RBC Bioscience Corporation

As of June 30, 2026, RBC Bioscience Corporation carries a market capitalization of 289.75M, placing it among publicly traded companies globally. Its enterprise value stands at 658.13M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, RBC Bioscience Corporation has 14.27M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, RBC Bioscience Corporation maintains a current ratio of 1.08, meaning it holds 1.1x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

As of the close on October 22, 2026, RBC Bioscience Corporation's stock has gained approximately 16.53% over the past 52 weeks. The 50-day moving average sits at 21.83, while the 200-day moving average is 19.10.

As of June 30, 2026, RBC Bioscience Corporation holds 43.18M in cash and equivalents against 411.56M in total debt, resulting in a net debt position of 367.53M. Total book value stands at 260.09M, with working capital of 10.34M providing operational flexibility.

RBC Bioscience Corporation's most recent stock split took place on August 11, 2025 with a 10:11 split ratio.